{"transactions":[{"id":2398335,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":49386,"kind":"person","name":"Voliotis Dimitris","position":1,"cik":"0001807910","reported_name":"Voliotis Dimitris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-15T02:10:45.000Z","date":"2022-02-10","kind":"grant","acquired":true,"shares":24234,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date."}],"balance_after":24234,"derivative":{"exercise_price":52.61,"expiration_date":"2032-02-09","underlying":"Common Stock","underlying_shares":24234},"source":{"system":"sec-edgar","filing":"0001725160-22-000035","document":"wf-form4_164489102664442.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1807910/000172516022000035/wf-form4_164489102664442.xml","form_type":"4"}},{"id":2398334,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":49386,"kind":"person","name":"Voliotis Dimitris","position":1,"cik":"0001807910","reported_name":"Voliotis Dimitris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Common Stock","published_at":"2022-02-15T02:10:45.000Z","date":"2022-02-14","kind":"sale","acquired":false,"shares":67,"price":50.7472,"value":3400.0624,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.58 to $50.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":15978,"source":{"system":"sec-edgar","filing":"0001725160-22-000035","document":"wf-form4_164489102664442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807910/000172516022000035/wf-form4_164489102664442.xml","form_type":"4"}},{"id":2398333,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":49386,"kind":"person","name":"Voliotis Dimitris","position":1,"cik":"0001807910","reported_name":"Voliotis Dimitris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Common Stock","published_at":"2022-02-15T02:10:45.000Z","date":"2022-02-14","kind":"sale","acquired":false,"shares":534,"price":50.1642,"value":26787.6828,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.58 to $50.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":16045,"source":{"system":"sec-edgar","filing":"0001725160-22-000035","document":"wf-form4_164489102664442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807910/000172516022000035/wf-form4_164489102664442.xml","form_type":"4"}},{"id":2398332,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":49386,"kind":"person","name":"Voliotis Dimitris","position":1,"cik":"0001807910","reported_name":"Voliotis Dimitris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Common Stock","published_at":"2022-02-15T02:10:45.000Z","date":"2022-02-10","kind":"grant","acquired":true,"shares":10329,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date."}],"balance_after":16579,"source":{"system":"sec-edgar","filing":"0001725160-22-000035","document":"wf-form4_164489102664442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807910/000172516022000035/wf-form4_164489102664442.xml","form_type":"4"}},{"id":2430729,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":49386,"kind":"person","name":"Voliotis Dimitris","position":1,"cik":"0001807910","reported_name":"Voliotis Dimitris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Stock Option","published_at":"2022-01-21T00:15:07.000Z","date":"2022-01-20","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The option vests and becomes exercisable as to 25% of the shares on March 25, 2021 and vests in equal monthly installments thereafter until March 25, 2024."}],"balance_after":124949,"derivative":{"exercise_price":18,"expiration_date":"2030-03-25","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001725160-22-000015","document":"wf-form4_164272409240773.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1807910/000172516022000015/wf-form4_164272409240773.xml","form_type":"4"}},{"id":2430728,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":49386,"kind":"person","name":"Voliotis Dimitris","position":1,"cik":"0001807910","reported_name":"Voliotis Dimitris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Stock Option","published_at":"2022-01-21T00:15:07.000Z","date":"2022-01-19","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The option vests and becomes exercisable as to 25% of the shares on March 25, 2021 and vests in equal monthly installments thereafter until March 25, 2024."}],"balance_after":134949,"derivative":{"exercise_price":18,"expiration_date":"2030-03-25","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001725160-22-000015","document":"wf-form4_164272409240773.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1807910/000172516022000015/wf-form4_164272409240773.xml","form_type":"4"}},{"id":2430727,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":49386,"kind":"person","name":"Voliotis Dimitris","position":1,"cik":"0001807910","reported_name":"Voliotis Dimitris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Stock Option","published_at":"2022-01-21T00:15:07.000Z","date":"2022-01-18","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The option vests and becomes exercisable as to 25% of the shares on March 25, 2021 and vests in equal monthly installments thereafter until March 25, 2024."}],"balance_after":144949,"derivative":{"exercise_price":18,"expiration_date":"2030-03-25","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001725160-22-000015","document":"wf-form4_164272409240773.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1807910/000172516022000015/wf-form4_164272409240773.xml","form_type":"4"}},{"id":2430726,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":49386,"kind":"person","name":"Voliotis Dimitris","position":1,"cik":"0001807910","reported_name":"Voliotis Dimitris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Common Stock","published_at":"2022-01-21T00:15:07.000Z","date":"2022-01-20","kind":"sale","acquired":false,"shares":1657,"price":61.2065,"value":101419.1705,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $61.01 to $61.61. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":6250,"source":{"system":"sec-edgar","filing":"0001725160-22-000015","document":"wf-form4_164272409240773.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1807910/000172516022000015/wf-form4_164272409240773.xml","form_type":"4"}},{"id":2430725,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":49386,"kind":"person","name":"Voliotis Dimitris","position":1,"cik":"0001807910","reported_name":"Voliotis Dimitris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Common Stock","published_at":"2022-01-21T00:15:07.000Z","date":"2022-01-20","kind":"sale","acquired":false,"shares":8343,"price":60.5183,"value":504904.1769,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $60.00 to $60.95. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":7907,"source":{"system":"sec-edgar","filing":"0001725160-22-000015","document":"wf-form4_164272409240773.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1807910/000172516022000015/wf-form4_164272409240773.xml","form_type":"4"}},{"id":2430724,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":49386,"kind":"person","name":"Voliotis Dimitris","position":1,"cik":"0001807910","reported_name":"Voliotis Dimitris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Common Stock","published_at":"2022-01-21T00:15:07.000Z","date":"2022-01-20","kind":"exercise","acquired":true,"shares":10000,"price":18,"value":180000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021."}],"balance_after":16250,"source":{"system":"sec-edgar","filing":"0001725160-22-000015","document":"wf-form4_164272409240773.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1807910/000172516022000015/wf-form4_164272409240773.xml","form_type":"4"}},{"id":2430723,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":49386,"kind":"person","name":"Voliotis Dimitris","position":1,"cik":"0001807910","reported_name":"Voliotis Dimitris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Common Stock","published_at":"2022-01-21T00:15:07.000Z","date":"2022-01-19","kind":"sale","acquired":false,"shares":555,"price":62.2352,"value":34540.536,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $62.15 to $62.41. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":6250,"source":{"system":"sec-edgar","filing":"0001725160-22-000015","document":"wf-form4_164272409240773.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1807910/000172516022000015/wf-form4_164272409240773.xml","form_type":"4"}},{"id":2430722,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":49386,"kind":"person","name":"Voliotis Dimitris","position":1,"cik":"0001807910","reported_name":"Voliotis Dimitris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Common Stock","published_at":"2022-01-21T00:15:07.000Z","date":"2022-01-19","kind":"sale","acquired":false,"shares":1556,"price":61.5085,"value":95707.226,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $61.09 to $61.94. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":6805,"source":{"system":"sec-edgar","filing":"0001725160-22-000015","document":"wf-form4_164272409240773.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1807910/000172516022000015/wf-form4_164272409240773.xml","form_type":"4"}},{"id":2430721,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":49386,"kind":"person","name":"Voliotis Dimitris","position":1,"cik":"0001807910","reported_name":"Voliotis Dimitris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Common Stock","published_at":"2022-01-21T00:15:07.000Z","date":"2022-01-19","kind":"sale","acquired":false,"shares":7889,"price":60.5505,"value":477682.8945,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $60.07 to $61.05. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":8361,"source":{"system":"sec-edgar","filing":"0001725160-22-000015","document":"wf-form4_164272409240773.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1807910/000172516022000015/wf-form4_164272409240773.xml","form_type":"4"}},{"id":2430720,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":49386,"kind":"person","name":"Voliotis Dimitris","position":1,"cik":"0001807910","reported_name":"Voliotis Dimitris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Common Stock","published_at":"2022-01-21T00:15:07.000Z","date":"2022-01-19","kind":"exercise","acquired":true,"shares":10000,"price":18,"value":180000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021."}],"balance_after":16250,"source":{"system":"sec-edgar","filing":"0001725160-22-000015","document":"wf-form4_164272409240773.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1807910/000172516022000015/wf-form4_164272409240773.xml","form_type":"4"}},{"id":2430719,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":49386,"kind":"person","name":"Voliotis Dimitris","position":1,"cik":"0001807910","reported_name":"Voliotis Dimitris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Common Stock","published_at":"2022-01-21T00:15:07.000Z","date":"2022-01-18","kind":"sale","acquired":false,"shares":1300,"price":64.6646,"value":84063.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $64.23 to $65.19. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":6250,"source":{"system":"sec-edgar","filing":"0001725160-22-000015","document":"wf-form4_164272409240773.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1807910/000172516022000015/wf-form4_164272409240773.xml","form_type":"4"}},{"id":2430718,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":49386,"kind":"person","name":"Voliotis Dimitris","position":1,"cik":"0001807910","reported_name":"Voliotis Dimitris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Common Stock","published_at":"2022-01-21T00:15:07.000Z","date":"2022-01-18","kind":"sale","acquired":false,"shares":1997,"price":63.4789,"value":126767.3633,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $63.18 to $64.02. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":7550,"source":{"system":"sec-edgar","filing":"0001725160-22-000015","document":"wf-form4_164272409240773.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1807910/000172516022000015/wf-form4_164272409240773.xml","form_type":"4"}},{"id":2430717,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":49386,"kind":"person","name":"Voliotis Dimitris","position":1,"cik":"0001807910","reported_name":"Voliotis Dimitris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Common Stock","published_at":"2022-01-21T00:15:07.000Z","date":"2022-01-18","kind":"sale","acquired":false,"shares":3294,"price":62.3358,"value":205334.1252,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $61.98 to $62.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":9547,"source":{"system":"sec-edgar","filing":"0001725160-22-000015","document":"wf-form4_164272409240773.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807910/000172516022000015/wf-form4_164272409240773.xml","form_type":"4"}},{"id":2430716,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":49386,"kind":"person","name":"Voliotis Dimitris","position":1,"cik":"0001807910","reported_name":"Voliotis Dimitris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Common Stock","published_at":"2022-01-21T00:15:07.000Z","date":"2022-01-18","kind":"sale","acquired":false,"shares":3409,"price":61.6972,"value":210325.7548,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $60.97 to $61.96. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":12841,"source":{"system":"sec-edgar","filing":"0001725160-22-000015","document":"wf-form4_164272409240773.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807910/000172516022000015/wf-form4_164272409240773.xml","form_type":"4"}},{"id":2430715,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":49386,"kind":"person","name":"Voliotis Dimitris","position":1,"cik":"0001807910","reported_name":"Voliotis Dimitris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Common Stock","published_at":"2022-01-21T00:15:07.000Z","date":"2022-01-18","kind":"exercise","acquired":true,"shares":10000,"price":18,"value":180000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021."}],"balance_after":16250,"source":{"system":"sec-edgar","filing":"0001725160-22-000015","document":"wf-form4_164272409240773.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807910/000172516022000015/wf-form4_164272409240773.xml","form_type":"4"}},{"id":2859543,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":49386,"kind":"person","name":"Voliotis Dimitris","position":1,"cik":"0001807910","reported_name":"Voliotis Dimitris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-17T00:01:42.000Z","date":"2021-02-11","kind":"grant","acquired":true,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date."}],"balance_after":18750,"derivative":{"exercise_price":38.76,"expiration_date":"2031-02-10","underlying":"Common Stock","underlying_shares":18750},"source":{"system":"sec-edgar","filing":"0001725160-21-000037","document":"wf-form4_161352006609320.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807910/000172516021000037/wf-form4_161352006609320.xml","form_type":"4"}},{"id":2859542,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":49386,"kind":"person","name":"Voliotis Dimitris","position":1,"cik":"0001807910","reported_name":"Voliotis Dimitris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Common Stock","published_at":"2021-02-17T00:01:42.000Z","date":"2021-02-11","kind":"grant","acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date."}],"balance_after":6250,"source":{"system":"sec-edgar","filing":"0001725160-21-000037","document":"wf-form4_161352006609320.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807910/000172516021000037/wf-form4_161352006609320.xml","form_type":"4"}}]}